Today's Company

PharmaEssentia

PharmaEssentia was born in 2003 from a bold scientific vision: that the fusion of biology and synthetic organic chemistry could unlock a new generation of breakthrough therapies. Driven by this belief, our founder invested his life savings, brought together a small circle of scientific pioneers, and established PharmaEssentia in a modest office at Taipei’s Nangang Software Park. From the beginning, our mission has been clear—to harness the power of innovation to tackle complex diseases and improve lives around the world. What started as a small, determined effort has grown into a global biopharmaceutical company, grounded in rigorous science, and guided by the same pioneering spirit that inspired our founding. What started as a bold dream has since become a beacon of innovation and hope—proof that one person’s conviction can spark a transformation far beyond their time and place.

News

ConcertAI and Foundation Medicine Integrate Genomic and Clinical Data to Transform Translational Research and Efficient Drug Development

ConcertAI, a leading oncology real-world evidence data and AI SaaS technology company, and Foundation Medicine, a global, patient-focused precision medicine company, announced a collaboration to combine their data assets for life sciences research. The collaboration brings Foundation Medicine’s expansive de-identified multimodal dataset derived from its genomic testing portfolio together with ConcertAI’s high-quality clinical data, to support more efficient drug development and real-world evidence research. With the addition of Foundation Medicine’s data, ConcertAI now offers the largest and most comprehensive clinically-linked dataset with nearly half a million patients.

Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan

Eisai Co., Ltd., a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc., a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced an exclusive license and collaboration agreement that significantly expands the long-term global footprint of taletrectinib (generic name, marketed as IBTROZI^® in the U.S. and Japan). Taletrectinib is a highly selective, next-generation oral treatment currently approved for patients living with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in the U.S., China, and Japan.

NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI

NVIDIA and Eli Lilly and Company announced a first-of-its-kind AI co-innovation lab focused on applying AI to tackle some of the most enduring challenges in the pharmaceutical industry. The lab brings together Lilly’s world-leading expertise in discovering, developing and manufacturing medicines with NVIDIA’s leadership in AI, accelerated computing and AI infrastructure. The two companies will invest up to $1 billion in talent, infrastructure and compute over five years to support the new AI co-innovation lab. Based in the San Francisco Bay Area, the lab will co-locate Lilly domain experts in biology, science and medicine with top AI model builders and engineers from NVIDIA, allowing them to work side by side to generate large-scale data and build powerful AI models that can accelerate medicine development, using NVIDIA BioNeMo™ as the critical platform.

GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug

The GARDP Foundation and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio 1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished.

BioMed X Launches XBridge Pilot to Facilitate Industry-Academic Research Collaborations

BioMed X announced today the launch of a pilot initiative with Harvard University under BioMed X’s XBridge framework to support structured research collaborations between academic investigators and pharmaceutical industry scientists through sponsored research agreements. The XBridge pilot is designed to connect senior biomedical researchers and principal investigators at Harvard with researchers from pharmaceutical companies seeking to explore collaborative research opportunities. The initiative aims to provide a transparent and structured mechanism for identifying areas of shared scientific interest and enabling dialogue that may lead to formal sponsored research collaborations facilitated by the Harvard Office of Technology Development.

Research & Study

A protein found in the GI tract can neutralize many bacteria

Russian scientists develop method to enhance effectiveness of anti-cancer medicines

Ultrasound-triggered nanocatchers turn tumors into personalized vaccines

Podcast

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

The Innovation Reckoning: Rethinking Indian Pharma’s Future

4^th Miami Workshop on Aerosol Science and Technology - Summer School in Winter

Video

Today's Company

Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities.

News

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List

Eisai Co., Ltd. and Biogen Inc. announced today that anti-Aβ protofibril* antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), has been included in the “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of LEQEMBI in this list marks a meaningful step toward expanding access to early Alzheimer’s Disease (AD) treatment in China.

Boehringer Ingelheim advances next generation triple-agonist peptide for the treatment of obesity into mid-stage development

Boehringer Ingelheim today announced the advancement of BI 3034701, its long‑acting potential first-in-class triple‑agonist peptide, in development for the treatment of obesity. This milestone reflects the company’s strategy to address the global burden of obesity and its interconnected cardiovascular, renal, metabolic (CRM) complications.

FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia

The U.S. Food and Drug Administration today announced it has approved Omisirge (omidubicel-onlv), the first hematopoietic stem cell transplant (HSCT) therapy to treat patients with severe aplastic anemia (SAA). Omisirge is indicated for adults and pediatric patients 12 years and older with hematologic malignancies and now is approved for adults and pediatric patients six years and older with SAA following reduced intensity conditioning and for whom a compatible donor is not available.

SeaBeLife enters into joint development agreement with Unither Pharmaceuticals to formulate and produce ophthalmic drug candidate

SeaBeLife, a biotechnology company developing innovative drug candidates intended to block cellular necrosis, today announces it has signed a joint development agreement with Unither Pharmaceuticals, a French pharmaceutical CDMO with an international footprint, specialized in the development and manufacture of sterile single doses. The agreement will lead to the production of clinical and commercial batches of the topical ophthalmic formulation of the SBL03 drug candidate. SBL03 is intended to treat degenerative disorders of the retina such as geographic atrophy and dry age-related macular degeneration (AMD).

JAX receives an up to $30M contract award to revolutionize drug safety testing with AI-powered “virtual hearts”

Developing new drugs is one of the riskiest and most expensive endeavors in science. The Jackson Laboratory announced a bold initiative to improve that trajectory, powered by an up to $30 million contract from the Advanced Research Projects Agency for Health (ARPA-H) Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) program. CATALYST is led by ARPA-H Health Science Futures Mission Office Acting Deputy Director Andy Kilianski, Ph.D.

Research & Study

Discovery of a β-arrestin-biased CCKBR agonist that blocks CCKBR-dependent long-term potentiation

Researchers from NUS Medicine and the Institute of Mental Health detect early brain changes linked to future psychosis development

Podcast

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

Do More With Less – Boost Lab Productivity Through Smarter Equipment

Strategic Approaches to Operational Excellence & Regulatory Compliance

Video

Today's Company

Nuravax

Nuravax is spearheading the use of immunotherapies in neurodegenerative disorders. We fully recognize the widespread impact of Alzheimer’s disease and other neurodegenerative conditions on millions of patients, caregivers, and families worldwide.Our revolutionary MultiTEP vaccine platform, built on over two decades of extensive research, was developed in collaboration with the Institute for Molecular Medicine, various universities, and the NIH.

News

AI start-up SandboxAQ creates new data to speed up drug discovery

SandboxAQ today announced the launch of SAIR (Structurally Augmented IC50 Repository), the largest-ever detailed dataset of protein-ligand pairs with annotated experimental potency data. Marking a major milestone in computational drug discovery, SAIR provides an unprecedented resource for researchers to advance AI models in drug discovery, significantly enhancing the speed and accuracy of binding affinity predictions.

MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its entry into a clinical master supply agreement with Roche for future studies investigating the combination of MAIA’s telomere-targeting agent ateganosine (THIO), sequenced with Roche’s checkpoint inhibitor (CPI), atezolizumab (Tecentriq®), for the treatment of multiple hard-to-treat cancers.

AbbVie’s Qulipta Demonstrates Superiority in Migraine Prevention

AbbVie today announced positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of atogepant (QULIPTA^® / AQUIPTA^®, 60 mg once daily) compared to the highest tolerated dose of topiramate (50, 75 or 100 mg/day) in adult patients with a history of four or more migraine days per month.

Incyte Partners with Qiagen to Create Diagnostic for Rare Blood Cancers

Incyte today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).

Research & Study

Endoscopic cancer screening may be ineffective for people over 80

Vitamin D could help people age slower

Researchers uncover mechanism behind moyamoya surgery complication

Podcast

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

Navigating the Complexities of Cell and Gene Therapy Logistics

Enabling RNA Modalities for Therapeutic Innovation: Harnessing Microfluidic Characterization

Video

Today's Company

Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

News

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, today announced a Cooperative Research and Development Agreement (CRADA) has been executed to advance the development of camonsertib as an anticancer agent in collaboration with the Cancer Therapy Evaluation Program (CTEP) of the US National Cancer Institute (NCI), part of the US National Institutes of Health.

U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. The FDA has cleared the Company to begin enrolling the planned Phase 3 trial following the determination that Novavax satisfactorily addressed all clinical hold issues. Novavax will be working with the clinical trial investigators and other partners to resume trial activities as quickly as possible.

Nutcracker Therapeutics Introduces CRDMO Precision Biomanufacturing Solutions for RNA Drug Developers

Nutcracker Therapeutics, Inc., a pioneering biotechnology company dedicated to enabling transformative RNA therapies through its proprietary technology platform, today announced its new contract research, development, and manufacturing organization (CRDMO) capabilities, which will provide next-generation design and biomanufacturing solutions for RNA drug developers.

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089

Cytokinetics Incorporated today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose clinical study of CK-4015089 (CK-089) in healthy human participants. CK-089 is a fast skeletal muscle troponin activator (FSTA) with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired muscle function.

Research & Study

New cancer therapy strategy targets GLUT3 in regulatory T cells to supercharge anti-tumor immunity

Mushroom Supplement Found to Slow Prostate Cancer

Vitamin D supplements during pregnancy improve child bone health

Podcast

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

Biologic therapies: Charting the path from injectables to inhalation

Dose Administration, Compatibility, and Clinical Usability of Biologics

Video

Today's Company

Lykos Therapeutics

Lykos Therapeutics, our mission is to transform mental healthcare. We’re applying decades of evidence-based research to develop investigational psychedelics to catalyze therapeutic approaches for mental health conditions. We are relentlessly exploring and reimagining novel approaches to address unmet needs in the mental healthcare space, with an initial focus on PTSD. As a Public Benefit Company, we are focused on delivering positive impact on our people, communities and society.

News

NSG BioLabs and Merck Collaborates to Support Biotech Start-ups to Advance Research & Innovations

NSG BioLabs, Singapore's largest provider of biotech co-working laboratory and office space, and the Life Science business of Merck Singapore, announce partnership giving biotech start-ups access to resources and expertise to bolster the research and development capabilities of NSG Biolabs' tenants, thereby facilitating opportunities for funding, partnerships, production, and commercialization.

Nanoform Collaborates with Takeda on Plasma-derived Therapy Development

Nanoform Finland Plc, the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of Takeda Pharmaceuticals, Inc., the R&D-driven biopharmaceutical company headquartered in Japan, to develop innovative plasma-derived therapy formulations for the treatment of rare conditions.

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Incyte and Syndax Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Niktimvo™ (axatilimab-csfr), an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs.).

iniuva and Enamine Announce Strategic Collaboration to Advance Drug Discovery for Rare Genetic Diseases

iniuva GmbH, a Hamburg-based pioneering biotech startup specializing in AI-powered drug discovery, and Enamine Ltd, a Kyiv-based leading provider of chemical compounds and related services, today announced a collaborative research and development program.The collaboration aims to revolutionize the efficiency and precision of small-molecule drug discovery, particularly in the realm of orphan drugs and pharmacological chaperones.

Research & Study

Antibiotics Could Target Bacterial Protein Found to Maintain Envelope Integrity

Researchers Hope to Use Vitamins to Displace Antibiotics and Zinc Oxide in Addressing Piglet Diarrhea

AI Tools Struggle with Patient Descriptions of Genetic Conditions

Podcast

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

Maximize Brand Success with Data-Driven Provider Market Insights

Accelerating Translational Research with High-Performance Automated InSituPlex® Assays

Video

Today's Company

MaaT Pharma

MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.

News

Acino signs an exclusive licensing and supply agreement with Allecra Therapeutics in Gulf Cooperation Council countries and South Africa

Allecra Therapeutics and Acino today announced the signing of an exclusive licensing agreement under which Acino gains the rights to commercialise Allecra’s antibiotic drug EXBLIFEP® (cefepime/enmetazobactam) within the Republic of South Africa and the member states of the GCC alliance, which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates, effective from 12 June 2024. In addition, the companies have signed a supply agreement under which Allecra will supply the cefepime/enmetazobactam finished product in the above territories.

4D Molecular Therapeutics to Kick off Phase I Gene Therapy Trial for Geographic Atrophy

4D Molecular Therapeutics , a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced U.S. Food and Drug Administration clearance of the Investigational New Drug Application (IND) for 4D-175, an R100 vector-based intravitreal genetic medicine, for the treatment of patients with GA.

Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data

Helix, a leading population genomics company and provider of precision medicine genomics solutions, today announced a groundbreaking multi-year agreement with Recursion Pharmaceuticals, a leading clinical-stage TechBio company decoding biology to industrialize drug discovery.

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

Takeda today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies. LIVTENCITY is the first and only post-transplant anti-CMV treatment approved in Japan that targets and inhibits pUL97 kinase and its natural substrates.

Research & Study

New study demonstrates the efficacy of a promising celiac disease drug at the molecular level

MIT researchers develop new algorithmic framework to identify molecules for drug discovery

Diabetes and Obesity Drugs May Reduce Risk of Dementia For Older Diabetes Patients

Sarecycline May Be Effective in Periorificial Dermatitis Treatment

Podcast

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

Management of common skin conditions and ailments in the community pharmacy

Rethinking Emerging Biopharma’s Relationships with CROs

Video

Today's Company

Lantern Pharma

Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR^®, leverages over 60+ billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in cancer drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of precision therapies.

News

Japanese Foundation for Cancer Research and Takeda Announce Collaboration on Research and Development

Japanese Foundation for Cancer Research and Takeda Pharmaceutical Company Limited announced today that they have signed a partnership agreement with the goal to advance research and development in the field of oncology.Under the terms of this agreement, JFCR and Takeda will engage in mutual exchange utilizing each other's strengths for the purpose of advancing global early clinical trials and facilitating translational research based on this agreement. This will include active information exchanging and consultation regarding ongoing drug development. The partnership seeks to expedite the development of groundbreaking anti-cancer therapies and facilitate their swift delivery to cancer patients and their families.

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

Ipsen and Skyhawk Therapeutics today announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases. The agreement includes an option pursuant to which Ipsen would acquire exclusive license for the worldwide rights to develop successful development candidates (DC). Following successful DC nomination, Ipsen will be responsible for all activities. Skyhawk's unique platform accelerates building RNA-targeting small molecules across several therapeutic areas, including rare neurological diseases.

Kynos Therapeutics announces positive top line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement

Kynos Therapeutics Ltd, a clinical stage biotechnology company developing first-in-class small molecule kynurenine 3-monooxygenase (KMO)  inhibitors for acute and chronic inflammatory disorders, today announces the key findings from the first in human Phase I trial of its lead drug candidate, KNS366.KMO is an enzyme that acts at a key point in the kynurenine pathway of tryptophan metabolism, converting kynurenine into 3-hydroxykynurenine (3-HK). By inhibiting KMO activity, KNS366 is designed to reduce elevated 3-HK in order to prevent excess tissue damage and dysregulation of the immune system occurring during inflammation.

Samsung Bioepis Initiates Phase 3 Clinical Trial for Proposed Pembrolizumab Biosimilar

Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for PYZCHIVA™, a biosimilar to Stelara (ustekinumab), paving the way for expanding its immunology portfolio. PYZCHIVA is approved for the treatment of certain autoimmune disorders in gastroenterology, dermatology and rheumatology. “We are proud to have our fourth immunology biosimilar approved in Europe,” said Byoungin Jung, Vice President and Regulatory Affairs Team Leader, at Samsung Bioepis. “With the latest approval, we are pleased to make an important progress towards providing additional treatment options for patients suffering chronic, autoimmune diseases in Europe.” 

Research & Study

Antibacterial and antibiofilm activities of iodinated hydrocarbons against Vibrio parahaemolyticus and Staphylococcus aureus

Molybdenum disulfide nanosheets promote the plasmid-mediated conjugative transfer of antibiotic resistance genes

Olesoxime protects against cisplatin-induced acute kidney injury by attenuating mitochondrial dysfunction

Artificial Intelligence Speeds Up Parkinson’s Drug Development

Podcast

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

BioTrinity 2024

Clinical Trial Supply Forum

Video

Today's Company

Acumen Pharmaceuticals, Inc.

Acumen is forging a new path towards safe and effective treatments for Alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic soluble amyloid-beta oligomers. Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field. We are now on the on cusp of realizing the therapeutic potential of Aβo targeted drugs.

News

New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)

Roche announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo^® (faricimab) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO). Whereas available RVO treatments are typically given every one to two months, the data showed nearly 60% of people receiving Vabysmo in BALATON and up to 48% of people in COMINO were able to extend their treatment intervals to three or four months apart. In addition, patients in the studies maintained vision gains and robust retinal drying achieved in the first 24 weeks of the studies for more than one year. Retinal drying is an important clinical measure as swelling from excess fluid in the back of the eye has been associated with distorted and blurred vision. In both studies, Vabysmo was well tolerated and the safety profile was consistent with previous studies.

Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa

Eisai Co., Ltd. announced today that fully-fledged operations have begun at Eisai Pharmaceuticals Africa , a pharmaceutical sales subsidiary recently established in Johannesburg, South Africa, and direct sales operations and business activities have commenced in Africa. Eisai South Africa is a wholly-owned subsidiary of Eisai.

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

Takeda and Protagonist Therapeutics, Inc., announced the signing of a worldwide license and collaboration agreement for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin, currently in a pivotal Phase 3 trial, VERIFY, for the treatment of Polycythemia Vera.

Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain. The Phase 3 program included two randomized, double-blind, placebo-controlled, pivotal trials, one following abdominoplasty surgery and one following bunionectomy surgery, as well as a single arm safety and effectiveness study which enrolled patients with a broad range of surgical and non-surgical pain conditions.

Research & Study

Eating up to three daily kimchi servings could reduce obesity risk in men

Arrangement of Bacteria in Biofilms Affects Their Sensitivity to Antibiotics

Podcast

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

20th Annual WORLDSymposium^™

How Filmcast PTFE Has Evolved Beyond Microcatheters

Video

Today's Company

Carina Biotech

Carina Biotech An Australian clinical stage immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. Carina are working towards producing broad-spectrum CAR-T therapies that can be used to treat multiple solid cancers yet are patient-specific and result in little, if any, off-cancer damage. Using its proprietary platforms, Carina is also developing technologies to improve access to, and infiltration of, solid cancers, and to enhance CAR-T cell manufacturing.

News

Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotech company focusing on the discovery and development of novel antibody therapeutics, today announces an antibody evaluation, option and license agreement with Ona Therapeutics , a Spanish biotech company specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer.Under the terms of the agreement, Biocytogen will grant Ona access to evaluate Biocytogen’s proprietary RenMice®-derived fully human antibodies against a specific tumor target, with an option to exclusively license selected antibodies for antibody-drug conjugate (ADC) development, manufacturing and commercialization in mutually agreed indications and territories.

Anagenex and Nimbus Announce a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Multiple Indications

Anagenex and Nimbus Therapeutics today announced they have initiated a research collaboration. Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence, will work closely with Nimbus to discover small molecule drugs for multiple challenging targets.Through this multi-target collaboration, the companies will apply Anagenex’s AI driven parallel biochemistry platform to generate billions of experimentally measured datapoints for each of Nimbus’ nominated targets. Anagenex will then use the resulting data to train proprietary AI models that will generatively design 100 million new target-specific molecules to experimentally probe structure activity relationships at an unprecedented scale and speed ultimately identifying highly selective and potent drug candidates.

Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a potential best-in-class KRAS G12D oral inhibitor as the lead program of its discovery and development collaboration with GenFleet Therapeutics . “We are pleased to announce this oral KRAS G12D inhibitor with a potential best-in-class profile as the lead program from our collaboration with GenFleet supporting our mission to bring needed therapies to patients with RAS pathway-driven cancers,” said Dan Paterson, President and Chief Executive Officer of Verastem Oncology. “Although there has been significant progress in therapeutics targeting KRAS mutations, there are currently no available therapies approved by the U.S. Food and Drug Administration targeting KRAS G12D, the most prevalent KRAS mutation across human cancers.

BioMap and GeneQuantum establish a strategic collaboration to jointly develop a series of next-generation ADC therapeutics

BioMap, a global leader in life science AI Foundation protein-centric Large Language Models, and GeneQuantum Healthcare , a global leader in ADC new drug development focused on innovative bioconjugation technologies, announced that they have entered into a strategic collaboration agreement to co-develop FIC/BIC ADC therapeutics for multiple targets. The partnership will combine GQ’s proprietary enzymatic site-specific conjugation technology platforms (iLDC® and iGDC®), linker-payload platform, with BioMap’s life science AI Foundation Large Language Model xTrimo and AI protein generation platform AIGP, to create novel ADCs addressing high unmet medical needs.

Research & Study

New AI Framework to Identify New Indications for Existing Drugs

mRNA-4157 Plus Pembrolizumab Continues to Improve RFS in High-Risk Melanoma

New discovery could expand the possibilities for medical use of Botox

Chia seeds have great potential to improve human health

Podcast

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

PepTalk - The Protein Science and Production Week

How to Get the Most Out of Nitinol for Your Medical Device Application

Video

Today's Company

Krystal Biotech, Inc.

Krystal Biotech, Inc., our mission is to make a meaningful difference in the lives of underserved patient populations suffering from debilitating skin diseases. We work to accomplish this goal through scientific innovation and operational excellence, believing that "nature operates in the shortest way possible" (Aristotle). The diseases for which we develop therapies provide inspiration for our day-to-day activities. There is clarity in purpose, a collective empathy driving us forward. Krystal was named after this clarity — a simple realization that we can do better. In doing so, we extend gratitude to the patients, caregivers, advocates and physicians dedicated to the diseases which unite us in purpose.

News

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. , a biotechnology company, today announced the completion of patient enrollment in a pair of Phase 3 trials to evaluate the safety and efficacy of oral simufilam versus placebo in Alzheimer's disease dementia. Simufilam is Cassava Sciences’ proprietary oral drug candidate. This investigational drug binds to altered filamin A protein in the brain and restores its normal shape and function. By targeting altered filamin A, simufilam may help patients with Alzheimer’s achieve better health outcomes.

Toragen, Inc. Announced Positive Safety Update from Cohort 1 of its Phase 1 Trial in Patients with Human Papillomavirus-Induced Cancer

Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from Cohort 1 of its Phase 1 trial of TGN-S11, its first drug candidate, in patients with HPV-associated cancers.

ExactCare and Tabula Rasa to Combine, Creating a Leading, Independent Pharmacy Care Management Company for Patients with the Most Complex Needs

ExactCare®, a national provider of medication management and comprehensive long-term pharmacy services and a Nautic Partners portfolio company, today announced that the acquisition of Tabula Rasa HealthCare, Inc.®, a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, is complete.

New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anticoagulant treatment

Bayer expands its Phase III OCEANIC clinical development program for the investigational drug asundexian by initiating a third clinical study, OCEANIC-AFINA. OCEANIC AFINA is a Phase III study investigating asundexian as a potential treatment in patients (≥65 years of age) with atrial fibrillation at high risk for stroke or systemic embolism who are deemed ineligible for oral anticoagulation treatment due to an increased risk of bleeding. OCEANIC-AFINA complements OCEANIC-AF, an ongoing Phase III study investigating the efficacy and safety of asundexian for the prevention of stroke or systemic embolism in people with AF at risk of stroke. Together, the results from OCEANIC-AFINA and OCEANIC-AF aim at providing robust evidence for the efficacy and safety of asundexian across a broad range of patients with AF, including those who are at high risk for both ischemic stroke or systemic embolism and major bleeding events.

Research & Study

Scientists created new antibody to combat breast cancer

New UK research institute launched for motor neurone disease

Podcast

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

MEDICA 2023

ACIPC International Conference

Video

Today's Company

Sosei Heptares

Sosei Heptares is a fully integrated biopharmaceutical company focused on bringing life-changing medicines based on world-class science to patients globally. Our vision is to become one of Japan’s global biopharmaceutical champions. Our global business combines our world-leading GPCR-targeted StaR® technology, structure-based drug design and early development capabilities in the UK with a highly experienced clinical development capability and a commercial operation in Japan. We are leveraging these capabilities to generate and advance a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases. We intend to develop these opportunities for patients in Japan and globally both internally and through our partnerships with global biopharmaceutical companies and emerging technology companies. Sosei Heptares operates from key locations in Tokyo and Osaka (Japan), London and Cambridge (UK) and Seoul (South Korea).

Transform the health of your community with the Earth’s most powerful plants! Ora Organics create supplements from the earth's most powerful plants to transform your health. From protein to vitamins to probiotics, Ora Organics do it all!

Key ideas from bestselling non-fiction books, distilled by experts into bitesize text and audio. Explore our vast library of over 5,500 titles and stay up-to-date with 40 new titles that are added each month. Join the reading revolution!

News

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SLS009, a novel and highly selective CDK9 inhibitor, for the treatment of acute myeloid leukemia (AML).

Cellipont Bioservices and Diakonos Oncology Corporation Collaborate to Develop Groundbreaking Therapy for Glioblastoma

Cellipont Bioservices, a leading CDMO in cell therapy development and manufacturing and Diakonos Oncology, announced today that they have entered into an agreement for the Process Development & cGMP Manufacturing of DOC1021, an autologous dendritic cell vaccine being manufactured for the treatment of glioblastoma multiforme (GBM) and other cancer indications.

Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract

Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, today announced the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), has awarded the company a contract to support the development of oral ceftibuten-ledaborbactam etzadroxil for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis.

Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S.

Bayer AG has opened a new cell therapy production plant in Berkeley, California, USA, to bring cell therapies to patients on a global scale. The USD 250 million investment will support the production of material required for clinical trials and potential commercial launch of BlueRock Therapeutics’ bemdaneprocel (BRT-DA01), an investigational cell therapy currently in evaluation for treating Parkinson’s Disease.

Dollar Flight Club is offering their Lifetime Membership for $129 (usually $1,690) for the next 24 hours. Lifetime Members get up to 90% off all flights for life! Fly roundtrip to Paris from $320, Hawaii from $197, and more. Get 93% off lifetime or try for free now.

Building tech is slow and expensive. Bubble is the most powerful no-code platform for creating digital products. Build better and faster.

Research & Study

Xenon’s Add-On Epilepsy Treatment Shows Promising Phase IIb Efficacy, Safety

New deep screening technique enables rapid discovery of high-affinity antibodies to clinically relevant drug targets

Podcast

Get One Free Month of Skillshare Explore thousands of hands-on creative classes with one inspiring membership.

DataCamp helps individual learners make better use of data. Build data skills online while learning from the world’s top data scientists. Help close the talent gap with DataCamp.

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

Covalent Drug Discovery: Basic Principles and Analysis of Current Patent Literature

Representativeness: A Failing Flaw in Traditional Clinical Trial Design

Video

Book the perfect Wander with inspiring views, modern workstations, restful beds, hotel-grade cleaning and 24/7 concierge service. It’s a vacation home, but better.

Buying Bitcoin is quick and easy with CoinSmart- The world's most accessible crypto exchange. Designed for beginners, built for experts. Instant verification, 24/7 support, fully registered, safe and secure.

Today's Company

Verge Genomics

Verge Genomics is a next-generation biopharmaceutical start-up using systems biology to accelerate development of life-saving treatments for neurodegenerative diseases. Our platform uses patient genomes, gene expression, and epigenomics to identify new therapeutic gene targets, predict effective drugs, and stratify patient subpopulations for increased clinical success. Verge's approach offers a breakthrough opportunity to identify drugs that dramatically improve patient outcomes and fundamentally lower the cost curve of pharmaceutical development.The startup nature of Verge Genomics provides multiple growth opportunities into other areas of the company. As one of the early employees at Verge, your work will have a direct impact on the foundation of a groundbreaking new drug development model. In addition to competitive compensation and benefits, we offer perks like unlimited vacation/sick days, on-site gym access, and free lunch.

News

Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases

Otsuka Pharmaceutical Co., Ltd. and Shape^TX, the programmable medicine company using AI and RNA to end genetic diseases, announced a multi-target collaboration to develop intravitreally-delivered adeno-associated viruses (AAVs) for ocular diseases, with options to add additional targets and tissue types. The companies will collaborate to apply Shape^TX’s AAVid™ capsid discovery platform and transgene engineering technology along with Otsuka’s expertise in genetic payload design and ophthalmology to develop novel treatment options for people living with serious eye diseases.

Mendus receives U.S. FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia (AML)

Mendus AB, a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that it has received Fast Track Designation from the U.S. Food and Drug Administration for the Company’s lead program, vididencel, for the treatment of Acute Myeloid Leukemia (AML) in complete remission with residual disease. Advantages of the Fast Track Designation include close and early interactions with the FDA to support accelerated approval, as well as the possibility of a “rolling review” for a subsequent market application.

Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Erdafitinib for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer with Susceptible FGFR Alterations

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Marketing Authorisation Application to the European Medicines Agency seeking approval of erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma , harbouring susceptible fibroblast growth factor receptor 3 genetic alterations, with disease progression during or following at least one line of therapy containing a programmed death receptor-1 or programmed death-ligand 1 inhibitor.

Myricx Enters into Antibody License Agreement with Biocytogen

Myricx Bio, a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates, announced an antibody license agreement with Biocytogen Pharmaceuticals Co., Ltd , a global biotech company focusing on the discovery of novel antibody therapeutics.The agreement will enable Myricx to develop and commercialize ADCs based on an antibody developed using Biocytogen’s proprietary RenMice^® platform and will expand Myricx’s ADC pipeline of proprietary monoclonal antibodies against important cancer targets to which it conjugates its first-in-class selective cytotoxic payloads based on potent inhibitors of N-MyristoylTransferase , a completely novel concept in the ADC space.

Research & Study

New drug shows promise in preventing cartilage loss from osteoarthritis

Preventive epilepsy treatment with vigabatrin does not improve neurocognitive development in TSC infants

New cell-based system may help speed treatment discovery

Podcast

Drug Pricing Challenges and Navigating The IRA

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

InnovatePharmaHealthcare 2023

European Drug Discovery Innovation & Outsourcing Programme

Video

Today's Company

vTv Therapeutics Inc.

vTv Therapeutics is a clinical stage biotech company committed to improving the lives of diabetes patients.vTv has a pipeline of clinical drug candidates developed using our innovative technology and led by our TTP399 program for the treatment of type 1 diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease, psoriasis, atopic dermatitis, renal disease, primary mitochondrial myopathy, and pancreatic cancer.

News

Nebraska Medicine & Helix Partner to Provide Precision Care in Nebraska to Help Find Health Issues Individually and Statewide

Helix, the leading population genomics and viral surveillance company in the nation, and Nebraska Medicine, the state’s largest hospital and leading academic health network, announced a partnership today to launch a population genomics program to drive precision medicine for all individuals in Nebraska called the Genetic Insights Project. The research program will identify participants’ risk for a variety of cancers and other potentially life-threatening diseases with a single test, with the goal of not only helping to improve the lives of individual patients but also identifying trends for everyone across the region.

Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation

Gilead Sciences, Inc. and Tentarix Biotherapeutics today announced that the companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases. Designed to enhance both therapeutic benefit and safety, these molecules have the potential to conditionally target immune cells related to disease pathways without activating other immune cells that may create adverse events.

Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept

Sandoz, a global leader in off-patent medicines, today releases positive results from the MYLIGHT Phase III confirmatory efficacy and safety study for its biosimilar aflibercept, for patients living with wet macular degeneration – a key development in its efforts to address this area of unmet medical need. Mylight (ClinicalTrials.gov NCT04864834) is part of a comprehensive biosimilar development program that encompasses analytical, preclinical, and a clinical study. The Mylight Phase III confirmatory efficacy and safety study met its primary efficacy endpoint, showing therapeutic equivalence in mean change of best corrected visual acuity (BCVA) from baseline to week 8 between the biosimilar aflibercept and the reference biologic, Eylea®. Safety, immunogenicity, and pharmacokinetics results further confirm that there is no clinically meaningful difference between the products.

Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma

Pfizer Inc. announced the U.S. Food and Drug Administration has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Approval was based on the results of the single-arm Phase 2 MagnetisMM-3 trial, and continued approval for this indication is contingent upon verification of clinical benefit in a confirmatory trial(s).

Research & Study

Artificial Intelligence Uncovers the Best Drug Combos To Prevent COVID Recurrence

Laser Treatment Shown to Slightly Enhance Dermal Delivery of Minoxidil for Those with Androgenetic Alopecia

Common Cold Virus Associated With Rare Blood Clotting Disorder

Podcast

Dr. Pranil Chandra and Dr. Luis Raez: Enabling Comprehensive Genomic Profiling in Lung Cancer

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

The Modern Lab Leader 2023

Patient-Centric Brand Growth with ChatGPT, Predictive AI and On-Demand Patient Journey

Video

Today's Company

Samsung Biologics

Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.

News

Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer

Iovance Biotherapeutics, Inc., a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced positive regulatory and clinical updates related to its registrational single-arm Phase 2 IOV-LUN-202 trial in post-anti-PD-1 NSCLC.

Medicines and Healthcare products Regulatory Agency authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults

GSK plc today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorized Arexvy (respiratory syncytial virus vaccine, adjuvanted) for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. This is the first time an RSV vaccine for older adults has been authorized for use in Great Britain by the MHRA.

Elsie Biotechnologies Announces Collaboration with GSK to Accelerate Oligonucleotide Discovery Technologies

Elsie Biotechnologies, Inc., a biopharmaceutical company unlocking the full potential of oligonucleotide therapeutics, announced today a research collaboration agreement with GSK plc to advance the discovery and development of Elsie’s innovative oligonucleotide discovery platform with the aim of finding novel oligonucleotides optimized for safety, efficacy, and delivery. The collaboration combines GSK's extensive expertise in DNA encoded library technologies with Elsie's drug discovery platform. The companies will begin an initial research period where GSK and Elsie will explore the platform capabilities. Throughout the research term, GSK may exercise an option to a non-exclusive license from Elsie for the discovery platform and P(V) chemistry technologies to employ in GSK’s own oligonucleotide drug discovery research.

NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3

NANOBIOTIX , a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV , one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3.

BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors

BeiGene , a global biotechnology company, and DualityBio, a next-generation ADC company, today announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors.“With one of the industry’s leading global oncology research teams, we are investing in highly impactful therapeutic modalities such as ADCs that complement our dynamic and growing pipeline in solid tumors,” said Lai Wang, Ph.D., Global Head of R&D at BeiGene. “Through this strategic partnership with DualityBio, we are well positioned to advance this asset globally alongside our initial internally discovered ADC assets with our end-to-end ADC manufacturing capabilities.”

Subscribe now

Research & Study

Scientists Use AI to Discover Drugs That Kill “Zombie Cells” and Fight Age-Related Diseases

Fecal transplants could be used to battle skin cancer

Ultrasound Triggered Tumor Metabolism Suppressor Induces Tumor Starvation for Enhanced Sonodynamic Immunotherapy of Breast Cancer

Best Buy is the #1 retailer for consumer electronics. We work hard every day to enrich the lives of consumers through technology, whether they come to us online, visit our stores or invite us into their homes.

Podcast

4 Medical Affairs Hacks for Time Management

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies

22nd Annual International Congress on the Future of Breast Cancer

Subscribe now

Today's Company

Insilico Medicine

Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in the USA, China, Canada, UAE, Belgium, UK, and Taiwan sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research. Insilico Medicine pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

Best Buy is the #1 retailer for consumer electronics. We work hard every day to enrich the lives of consumers through technology, whether they come to us online, visit our stores or invite us into their homes.

News

NHS rolls out new ‘lifeline’ combination therapy for hundreds of women with womb cancer

Hundreds of women with advanced womb cancer in England are to be offered a new ‘lifeline’ option from today, as the NHS rolls out a life-extending new combination therapy that can halt the progression of the disease for twice as long as chemotherapy. The NHS has agreed landmark commercial deals for two drugs from different manufacturers, which will be used in combination to treat advanced endometrial cancer in between 500 and 750 women each year.

Regeneron Says Supreme Court Ruling Ends Patent Dispute With Amgen

Regeneron Pharmaceuticals, Inc. applauds the United States Supreme Court’s unanimous opinion ending a nearly decade-long patent dispute related to the Regeneron-invented PCSK9 inhibitor, Praluent® (alirocumab). The decision affirms the United States Court of Appeals for the Federal Circuit’s opinion, which held that Amgen’s asserted U.S. PCSK9 patent claims were invalid.

OmicsEdge Forms Strategic Partnership with Almaden Genomics to Streamline Drug Discovery

OmicsEdge has launched an industry leading drug discovery service that leverages Almaden’s g.nome™ platform to streamline the iteration process. The service makes it easy for labs to conduct a quick analysis of a patient or trial participant’s medical condition and genomics, gaining valuable insight in genomic criteria and how it affects elevated risk. The service can be used to significantly accelerate the drug discovery process and eliminate trial-and-error with abilities such as identifying causal variants that make ideal drug targets.

HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics

Shanghai Stock Exchange listed company HitGen Inc. announced today that it has entered into a research agreement with ARase Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics targeting ADP-ribose hydrolases, novel targets that function in therapeutically proven cancer stress pathways. HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify novel inhibitors of ARase’s validated oncology targets. HitGen will also support ARase programs from hit-to-lead chemistry to pre-clinical development. 

KSQ Therapeutics And Takeda Expand Strategic Immuno-Oncology Collaboration To Identify And Validate Novel Tumor Targets

KSQ Therapeutics, a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, announced today that it has expanded its strategic collaboration with Takeda to research and validate novel tumor-intrinsic targets. Under the terms of the agreement, Takeda will provide KSQ with an upfront payment and an investment in the double-digit millions of dollars. KSQ is also eligible to receive up to $510 million in future payments if all milestones are achieved during the term of the agreement, plus royalties on potential net sales of any commercial product resulting from the collaboration.

Research & Study

Vitamin K-dependent carboxylation regulates Ca²⁺ flux and adaptation to metabolic stress in β cells

Study investigates how running affects brain response to food cues

Resveratrol Loaded by Folate-Modified Liposomes Inhibits Osteosarcoma Growth and Lung Metastasis via Regulating JAK2/STAT3 Pathway

Podcast

Drug Approvals And Launches From A Legal Perspective

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Create amazing content quickly with Canva – no design skills needed

Upcoming Webinar & Event

PMRC (Pharma Market Research Conference) Europe

Optimize Your Local Pharmacovigilance and Medical Information Activities

As the pharmaceutical industry continues to evolve, independent pharmacies face numerous challenges, including shrinking margins on prescription dispensing and growing competition from large chains. MakoRx Care Connect recognizes these struggles and aims to empower independent pharmacies by providing them with the tools and resources needed to thrive in a changing market. 

Addressing Decreasing Revenues through Clinical Services 

Independent pharmacies have long relied on revenue generated from dispensing medications. However, with decreasing reimbursements, pharmacies must expand their services to remain competitive. 

MakoRx Care Connect helps local pharmacies tap into the growing demand for clinical services, such as point-of-care testing and telehealth consultations. By diversifying their offerings, pharmacies can generate new revenue streams and better serve their communities. 

Tackling the Doctor's Appointment Shortage 

With the increasing shortage of available doctor's appointments, patients often face long wait times and difficulty accessing timely care. MakoRx Care Connect bridges this gap by connecting patients to local pharmacies that offer cash-pay patient services and treatment. 

By leveraging the expertise of pharmacists and integrating telehealth services, patients can access the care they need quickly and conveniently in their local pharmacy. 

Eliminating Insurance Hassles with Cash-pay Services 

Navigating the complexities of insurance can be time-consuming and frustrating for both patients and healthcare providers. MakoRx Care Connect offers a solution by promoting cash-pay services, which simplify the payment process and lower costs for patients. By sidestepping insurance-related challenges, pharmacies can focus on delivering quality care while patients enjoy a more streamlined experience with no surprise bills. 

Harnessing the Power of Telehealth and In-person Services 

MakoRx Care Connect recognizes the value of combining telehealth services with in-person care. By partnering with virtual healthcare companies, independent pharmacies can offer patients the best of both worlds: convenient remote consultations combined with in-person services. 

This hybrid approach to healthcare not only expands a pharmacy's reach but also enhances patient satisfaction and fosters stronger relationships between pharmacists and their communities. 

Simplifying CLIA Applications for Pharmacies 

In order to provide point-of-care testing and other clinical services, independent pharmacies need to obtain Clinical Laboratory Improvement Amendments (CLIA) certification. 

MakoRx Care Connect offers support by helping pharmacies navigate the CLIA application process, ensuring they meet all necessary requirements and can begin offering these valuable services as soon as possible. 

Join the MakoRx Care Connect Network and Transform Your Pharmacy 

Independent pharmacies have a unique opportunity to enhance their service offerings, improve patient experiences, and boost revenue by partnering with MakoRx Care Connect. With a focus on supporting local pharmacies and streamlining patient services, MakoRx Care Connect is poised to revolutionize the way independent pharmacies operate in today's healthcare landscape. 

Don't miss out on the opportunity to strengthen your pharmacy's position in the market and better serve your community. Visit MakoRx to learn more about how the Care Connect platform can empower your pharmacy to thrive in a rapidly changing industry.

Subscribe now

Building leadership skills, motivating teams and developing strategies are all important aspects in today’s ever-changing health care landscape. Suryakumar Atmuri, Outpatient Pharmacy Director at Kaiser Permanente South San Francisco, shares his experience in pharmacy management as he confers his MBA degree from University of Louisiana, Lafayette.

Suryakumar Atmuri's early experiences in India, where he grew up in the city of Vijayawada, provided a foundation for his interest in pharmaceutical drug distribution. At a young age, he followed his father as he supplied medicines to rural areas, gaining an early appreciation for the importance of healthcare access.

This passion continued throughout his academic career, where he excelled in STEM subjects and graduated as valedictorian from his pharmacy school class of 100 students.

Upon moving to the United States to pursue his career, Atmuri volunteered at St. Francis Memorial Hospital before becoming a pharmacy technician and intern at Walgreens. Over 13 years at Walgreens, he held several roles, including pharmacist technician, intern, staff pharmacist, and pharmacy manager at Santa Clara, CA. During his time at Walgreens, he was involved in the launch of their proprietary pharmacy system, intercom plus, and contributed to its deployment in his district.

While still at Walgreens, Atmuri joined Kaiser Permanente as a per-diem pharmacist at the Fremont location in 1998. He worked simultaneously at Walgreens as a manager and part-time lead pharmacist at Kaiser until moving full- time to Kaiser as an outpatient pharmacy operations manager at the South San Francisco location in 2009. In this role, he improved pharmacy service and maintained high-quality care for Kaiser members as the outpatient pharmacy director.

At Kaiser, Atmuri led multiple corporate pilots for clinical services and technology implementations, including pharmacist naloxone furnishing and the outpatient pharmacy management system (EPIMS) rollout. In addition, he was instrumental in developing associated playbooks and their monitoring measures. He also managed a large group of patient staff and led his department to achieve the pharmacy region's top performer in JD Power service satisfaction scores for several years. As a result, corporate and his peer directors often consulted him on operational efficiency opportunities.

Atmuri attributes his leadership success to his ability to learn and grow through staff empowerment, communication, and effective decision-making. With over 28 years of experience in a pharmacy, 25 of which were with Kaiser Permanente, he continues to strive for improvement by applying the skills acquired through his MBA program.

Share

Gigi: Congratulations on receiving your MBA degree and thank you for sharing your insights with us. Let’s start with this question. What does leadership mean to you?

Suryakumar: Leadership in pharmacy means effectively guiding and inspiring a team of healthcare professionals to provide high-quality patient care. It involves having a clear vision for the pharmacy's role in the more extensive healthcare system, setting goals and objectives, and motivating and empowering team members to achieve those goals. It also means navigating complex regulatory and financial challenges while maintaining a patient-centered focus.

Gigi: How do you describe or define your leadership style?

Suryakumar: My leadership style is collaborative and empowering. I believe in involving team members in decision-making and encouraging open communication and feedback. I also prioritize empowering team members to take ownership of their work and develop their skills and expertise.

Gigi: What is the most challenging part of the MBA program?

Suryakumar: Keeping up with a busy work schedule and spending 15-20 hours per week to study for tests and write reports.

Gigi: How would you apply what you learned from the MBA program in your current everyday operation?

Suryakumar:I plan to apply what I learned from the MBA program in my everyday operations by utilizing the best leadership, strategy, and management practices. For example, I can use data-driven decision-making and project management techniques to optimize pharmacy operations and improve patient outcomes. I can also apply finance and accounting principles to develop more effective budgeting and cost management strategies.

Gigi: Who is your inspiration?

Suryakumar: My inspiration is my father, who worked for a pharmaceutical distributor and was a successful business owner. He instilled in me a passion for pharmacy and a commitment to delivering high-quality patient care. He also taught me the importance of hard work, dedication, and continuous learning.

Gigi: Knowing what you know right now, would you still choose this career path?

Suryakumar: Yes, I would still choose this career path. The pharmacy industry is constantly evolving, and it is an exciting opportunity to impact patient care and healthcare outcomes positively. My MBA education has prepared me well for the challenges and opportunities in this field.

Gigi: What should pharmacy students do to acquire leadership skills?

Suryakumar: To acquire leadership skills, pharmacy students should seek opportunities to develop communication, teamwork, and decision-making abilities. This can involve participating in student organizations, internships, and volunteer work, as well as seeking mentors and networking with professionals in the field. Additionally, pursuing advanced education such as an MBA can provide a strong foundation in leadership, strategy, and management.

Gigi: Thanks again for your interview. Best of luck with your future endeavors.

Subscribe now

Gigi Chung is a pharmacist at Kaiser Permanente South San Francisco.

She has served in consultant roles for skilled nursing facilities and nursing homes in the greater San Francisco Bay Area.

She is currently working on different clinical projects and pursuing Advanced Practice credentials in California.

Subscribe now

Today's Company

Horizon Therapeutics

Horizon Therapeutics believes science and compassion must work together to transform lives. Our mission to deliver medicines for rare, autoimmune and severe inflammatory diseases and provide compassionate support comes from our strong and simple philosophy to make a meaningful difference for patients and communities in need.

News

Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA

Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for proposed biosimilar denosumab. The application includes all indications covered by the reference medicines Prolia^® (denosumab)* and Xgeva^® (denosumab)* for treating a variety of conditions, including osteoporosis in postmenopausal women and in men at increased risk of fractures, treatment-induced bone loss, prevention of skeletal-related complications in cancer that has spread to the bone, giant cell tumor of the bone, and treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

Roche announces positive data from global phase III program for crovalimab in PNH, a rare life-threatening blood condition

Roche today announced positive results from the global phase III COMMODORE 2 study, evaluating the efficacy and safety of crovalimab in people with paroxysmal nocturnal hemoglobinuria (PNH) who have not been previously treated with complement inhibitors. The study met its co-primary efficacy endpoints of transfusion avoidance and control of hemolysis (the ongoing destruction of red blood cells measured by lactate dehydrogenase levels). Results showed that crovalimab, a novel, investigational anti-C5 recycling monoclonal antibody, given as a subcutaneous injection every four weeks, achieved disease control and was non-inferior to eculizumab, a current standard of care, which is given intravenously every two weeks.

Forxiga approved in the EU for the treatment of symptomatic chronic heart failure

Forxiga (dapagliflozin) has been approved in the European Union to extend the indication for heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of left ventricular ejection fraction (LVEF), including HF with mildly reduced and preserved ejection fraction (HFmrEF, HFpEF). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use in December 2022 and was based on the positive results from the DELIVER Phase III trial. Results from the prespecified pooled analysis of DELIVER and DAPA-HF Phase III trials also established Forxiga as the first HF medication to demonstrate a mortality benefit across the full ejection fraction range.

Tavneos® (avacopan) is approved in Australia for the treatment of ANCA-associated vasculitis

Vifor Fresenius Medical Care Renal Pharma today announced the Therapeutic Goods Administration in Australia has approved Tavneos® in combination with rituximab or cyclophosphamide-based regimen for the treatment of adults with anti-neutrophil cytoplasmic autoantibody (ANCA) – associated vasculitis (granulomatosis polyangiitis [GPA] or microscopic polyangiitis [MPA]); two main forms of AAV. Tavneos® was granted orphan drug designation by the TGA and is the first targeted therapy for AAV and the first approved in a decade.

Research & Study

Immunosuppressive drug methotrexate linked to increased risk of three types of skin cancer

Early interruption of breastfeeding and sugar consumption contributes to dental caries by age 2

Kidney dialysis-related infection rates higher in U.S. minorities

The world’s smartest, clinically-proven ovulation and fertility tracker. Mira Fertility has empowered thousands of women to know better about their fertility and health!

Podcast

What we can expect for the obesity market in 2023 and a recap of drugs approved last year

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

SVB Securities Global Biopharma Conference

Biosynthesis of Chiral Compounds at Hiray Pharma Solutions

Today's Company

Prospection

Prospection is a Pioneer in healthcare data analytics. Using predictive analytics and machine learning with real world healthcare data to unearth insights that help research, develop and target better healthcare outcomes for patients. Founded out of Sydney’s Cicada Innovations in 2012, Prospection works with government, pharmaceutical companies and the medical community across more than 70 therapy programs, including immuno-oncology, HIV and hepatitis.

News

Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, is pleased to announce that the United States Food and Drug Administration (“U.S. FDA”) has granted Orphan Drug Designation (ODD) to Ifenprodil as a treatment for Idiopathic Pulmonary Fibrosis (IPF). Ifenprodil is the sole active ingredient in NP-120, an NMDA receptor antagonist and the Company’s lead clinical candidate being developed for the treatment of IPF and chronic cough.

European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS

Biogen Inc. announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for review of tofersen, an investigational drug for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). SOD1-ALS is a progressive and uniformly fatal disease that affects less than 1,000 people in Europe. There is currently no treatment targeted for SOD1-ALS.

Novartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer

Novartis announced the pivotal Phase III PSMAfore study with PluvictoTM  vipivotide tetraxetan), a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, met its primary endpoint. Pluvicto demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) in patients with PSMA–positive metastatic castration-resistant prostate cancer (mCRPC) after treatment with androgen-receptor pathway inhibitor (ARPI) therapy, compared to a change in ARPI1. No unexpected safety findings were observed in PSMAfore; data are consistent with the already-well established safety profile of Pluvicto.

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

 Pfizer Inc. and BioNTech SE today announced that the companies have submitted an application to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age. With the high level of respiratory illnesses currently circulating among children under 5 years of age, updated COVID-19 vaccines may help prevent severe illness and hospitalization.

Research & Study

AI Identifies Patients at Risk of Diabetes

New blood test can detect ‘toxic’ protein years before Alzheimer’s symptoms emerge

New technique to make complex molecules for antibiotics and anti-fungal medicines

Podcast

Listen to 157 - Everything Will Be Ao-K+: Potassium Formulations And Dosing For Hypokalemia and 170 more episodes by HelixTalk - Rosalind Franklin University's College Of Pharmacy Podcast, free! No signup or install needed. 157 - Everything Will Be ao-K+: Potassium Formulations and Dosing for Hypokalemia. 156 - There Is an App for That: Digital Health Advancements and More!.

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

A Tumor Microenvironment-Based Multiomics Analysis for Predictive Modelling

Building Efficiency into Biologics Formulations Development

Video

Today's Company

Terremoto Biosciences

Terremoto Biosciences is a covalent drug discovery and development engine creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy. The company leverages the power of lysine-based covalency across the disease spectrum to develop both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Many of Terremoto’s founders helped establish this emergent area of science, with the intent to broaden the number of tractable targets and deliver medicines with superior therapeutic benefit. Terremoto is supported by leading investors OrbiMed and Third Rock Ventures.

News

Ionis partners with Metagenomi to add gene editing to its broad technology platform

Ionis Pharmaceuticals, Inc. and Metagenomi today announced that the companies have entered a collaboration that will leverage Ionis' extensive expertise in RNA-targeted therapeutics and Metagenomi's versatile next-generation gene editing systems to pursue a mix of validated and novel genetic targets that have potential to expand therapeutic options for patients. The companies will jointly conduct research aimed initially at delivering investigational medicines for up to four genetic targets. Ionis has the right to add four more targets upon achievement of pre-determined development milestones.

Daewoong and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

HitGen Inc. today announced that it has entered into a research collaboration agreement with DAEWOONG PHARMACEUTICAL Co., Ltd, a global healthcare group in the Republic of Korea, dedicated to improving the quality of patients' lives. HitGen will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis and screening of thousands of DELs that collectively comprise over 1.2 trillion small, drug-like molecules to discover compounds that bind to certain targets that Daewoong needs to discover for new drug development.

Commencement of Ph2a trial for EP395 in COPD patients

EpiEndo Pharmaceuticals, the clinical-stage biopharmaceutical company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients. EP395 is an orally available macrolide or ‘Barriolide™,’ with reduced antimicrobial resistance potential, which aims to address the unmet medical need for a treatment for COPD.

ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer

 ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval for ELAHERE™ (mirvetuximab soravtansine-gynx) for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.

Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments

 Exscientia plc and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD Anderson in order to advance novel small-molecule oncology therapies.

Research & Study

Stanford researchers say they cured diabetes in mice

Melanoma Maneuvers Mortality by Maintaining Telomeres

Unique peptides with anti-cancer potential discovered

Podcast

Listen to 156 - There Is An App For That: Digital Health Advancements And More! and 169 more episodes by HelixTalk - Rosalind Franklin University's College Of Pharmacy Podcast, free! No signup or install needed. 156 - There Is an App for That: Digital Health Advancements and More!. 155 - Oncology 911: Tumor Lysis Syndrome as an Oncologic Emergency.

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

Single-Cell, Spatial, & In Situ Hi-Res Mapping of the Breast Cancer Tumor Microenvironment

mRNA Synthesis Considerations for Vaccine and Therapeutic Development

Video